|
Completed Clinical Studies
Principal Investigator, GlaxoSmithKline
ADG20001: A Multicenter, Randomized, Double-Blind, Double-Dummy,
Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy Safety and
Tolerability of Oral GW677954 Capsules (2.5, 5, 10, 15 and 20 Mg Once A Day) As
A Monotherapy (Diet and/or exercise treated) Or As An Add-On to Metformin for 16
Weeks Duration in Subjects with Type 2 Diabetes Mellitus”.
Principal Investigator, Aventis Pharmaceuticals
HOE901/4045: Glycemia Optimization Treatment
“GOT”: To Assess the Safety of Glucose Control as Measured By the Frequency of
Severe Hypoglycemia events Using Dosing Algorithms Based on Different Fasting
Blood Glucose Goals With Lantus (Insulin Glargine (rDNA Origin) In Adult
Individuals With Type 2 Diabetes Who Have Not Achieved the Target A1c Goal of
<7% With Oral Hypoglycemia Agents: A Randomized, Open-Label, Paralleled-Design
Trial.
Principal
Investigator, AstraZeneca
ZD4522A
Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of
Rosuvastin (Crestor) 20mg in the Primary Prevention of Cardiovascular Events
Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-ReactiveProtein.
Principal Investigator, Pfizer, Inc
A2171028: Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared
with Subcutaneous Human insulin in the Therapy of Adult Subjects with
Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma: A One-Year,
Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group
Comparative Trial.
Principal Investigator, Pfizer, Inc
Dr. A2171030: Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared
with Subcutaneous Human insulin in the Therapy of Adult Subjects with Type 1 or
Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year,
Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative
Trial.
|
Sitemap